Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) EVP Joseph Larosa sold 4,466 shares of the firm's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the completion of the transaction, the executive vice president owned 38,906 shares of the company's stock, valued at $37,563,353.94. This trade represents a 10.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Regeneron Pharmaceuticals Stock Performance
Shares of REGN stock opened at $930.67 on Thursday. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $95.82 billion, a P/E ratio of 20.55, a P/E/G ratio of 1.45 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $591.52 and a 12-month high of $991.73. The business's 50 day moving average is $800.69 and its two-hundred day moving average is $741.11.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts' consensus estimates of $16.51 by $3.56. The business had revenue of $5.12 billion during the quarter, compared to analysts' expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company's quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.83 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 51.64 EPS for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals's dividend payout ratio is 8.30%.
Institutional Investors Weigh In On Regeneron Pharmaceuticals
Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $473,872,000. Bank of New York Mellon Corp acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $472,950,000. Deutsche Bank AG bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $323,249,000. Finally, Man Group plc bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $272,460,000. Institutional investors and hedge funds own 83.31% of the company's stock.
Analysts Set New Price Targets
REGN has been the topic of a number of research analyst reports. Leerink Partners boosted their target price on Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the company a "market perform" rating in a research report on Monday. UBS Group raised shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the company from $660.00 to $978.00 in a research note on Thursday, October 15th. Raymond James Financial raised their price objective on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. Finally, Citigroup boosted their price target on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the stock a "neutral" rating in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $898.97.
View Our Latest Stock Analysis on REGN
Key Regeneron Pharmaceuticals News
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
- Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
- Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.
Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
